Syros Pharmaceuticals (NASDAQ:SYRS) Coverage Initiated by Analysts at StockNews.com

Stock analysts at StockNews.com initiated coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS) in a report issued on Monday. The brokerage set a “sell” rating on the stock.

A number of other analysts have also issued reports on SYRS. HC Wainwright reaffirmed a “neutral” rating and issued a $1.00 price target (down from $6.00) on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. JMP Securities restated a “market perform” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. Brookline Capital Management reiterated a “hold” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. Finally, TD Cowen restated a “hold” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and one has issued a buy rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $3.33.

Syros Pharmaceuticals Stock Performance

NASDAQ:SYRS opened at $0.20 on Monday. The company has a debt-to-equity ratio of 1.97, a quick ratio of 2.25 and a current ratio of 2.25. The stock has a market capitalization of $5.37 million, a PE ratio of -0.07 and a beta of 1.33. Syros Pharmaceuticals has a fifty-two week low of $0.18 and a fifty-two week high of $8.17. The company has a fifty day moving average of $1.17 and a two-hundred day moving average of $2.86.

Syros Pharmaceuticals (NASDAQ:SYRS) last released its quarterly earnings results on Thursday, October 31st. The company reported ($0.68) earnings per share for the quarter, topping the consensus estimate of ($0.76) by $0.08. During the same quarter last year, the company posted ($1.35) EPS. As a group, research analysts forecast that Syros Pharmaceuticals will post -2.94 earnings per share for the current fiscal year.

Insider Activity at Syros Pharmaceuticals

In other Syros Pharmaceuticals news, Director Nancy A. Simonian sold 134,713 shares of the company’s stock in a transaction on Monday, November 25th. The stock was sold at an average price of $0.27, for a total transaction of $36,372.51. Following the transaction, the director now directly owns 41,070 shares in the company, valued at $11,088.90. This represents a 76.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 12.26% of the stock is owned by insiders.

Institutional Trading of Syros Pharmaceuticals

Large investors have recently modified their holdings of the stock. GSA Capital Partners LLP acquired a new position in Syros Pharmaceuticals during the 3rd quarter worth $34,000. Certuity LLC acquired a new position in shares of Syros Pharmaceuticals during the second quarter worth about $109,000. Acadian Asset Management LLC increased its stake in shares of Syros Pharmaceuticals by 101.5% during the second quarter. Acadian Asset Management LLC now owns 34,578 shares of the company’s stock worth $178,000 after buying an additional 17,416 shares during the period. Finally, Exome Asset Management LLC raised its holdings in Syros Pharmaceuticals by 87.6% in the third quarter. Exome Asset Management LLC now owns 298,575 shares of the company’s stock valued at $642,000 after acquiring an additional 139,400 shares in the last quarter. Hedge funds and other institutional investors own 91.47% of the company’s stock.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.